在婴儿中米卡芬净的安全性、有效性和暴露-反应：应用已建立的药代动力学模型到电子健康记录。
Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.
机构信息
From the Duke Clinical Research Institute.
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
出版信息
Pediatr Infect Dis J. 2019 Feb;38(2):e26-e28. doi: 10.1097/INF.0000000000002045.
Abstract
Micafungin is used off-label in the United States to treat invasive candidiasis in neonates. We used an established pharmacokinetic model to determine micafungin exposures for 46 courses in 39 hospitalized infants. In this small cohort of infants, micafungin exposure was not associated with laboratory markers of liver toxicity, death or failure of microbiologic clearance.
摘要
米卡芬净在美国被超适应证用于治疗新生儿侵袭性念珠菌病。我们使用已建立的药代动力学模型来确定 39 名住院婴儿的 46 个疗程的米卡芬净暴露情况。在这个小婴儿队列中，米卡芬净的暴露与肝毒性、死亡或微生物清除失败的实验室标志物无关。
相似文献
1
Safety, Effectiveness and Exposure-response of Micafungin in Infants: Application of an Established Pharmacokinetics Model to Electronic Health Records.在婴儿中米卡芬净的安全性、有效性和暴露-反应：应用已建立的药代动力学模型到电子健康记录。
Pediatr Infect Dis J. 2019 Feb;38(2):e26-e28. doi: 10.1097/INF.0000000000002045.
2
Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials.米卡芬净在新生儿念珠菌病中的暴露-反应分析：两项临床试验的汇总分析。
Pediatr Infect Dis J. 2018 Jun;37(6):580-585. doi: 10.1097/INF.0000000000001957.
3
Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.氟康唑和米卡芬净在患有全身性念珠菌病的新生儿中的药代动力学和安全性：一项随机、开放标签的临床试验。
Br J Clin Pharmacol. 2018 Sep;84(9):1989-1999. doi: 10.1111/bcp.13628. Epub 2018 Jun 21.
4
Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.体外膜肺氧合支持下米卡芬净在婴儿中的药代动力学及安全性
Pediatr Infect Dis J. 2016 Nov;35(11):1204-1210. doi: 10.1097/INF.0000000000001268.
5
A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis.一项比较米卡芬净与两性霉素 B 去氧胆酸盐治疗侵袭性念珠菌病婴儿的 3 期研究。
Pediatr Infect Dis J. 2018 Oct;37(10):992-998. doi: 10.1097/INF.0000000000001996.
6
High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.大剂量米卡芬净用于患有侵袭性和中枢神经系统念珠菌病的早产新生儿和婴儿
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7333-7339. doi: 10.1128/AAC.01172-16. Print 2016 Dec.
7
Validation of Heel Stick Microsampling To Optimize Micafungin Doses in Neonates and Young Infants.足跟微量采血法优化新生儿和婴儿米卡芬净剂量的验证。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01199-18. Print 2018 Oct.
8
Pharmacokinetics of an elevated dosage of micafungin in premature neonates.米卡芬净高剂量在早产儿中的药代动力学。
Pediatr Infect Dis J. 2009 May;28(5):412-5. doi: 10.1097/INF.0b013e3181910e2d.
9
A Regulatory Review Approach for Evaluation of Micafungin for Treatment of Neonatal Candidiasis.一种评价米卡芬净治疗新生儿念珠菌病的监管审查方法。
Clin Infect Dis. 2021 Dec 16;73(12):2335-2340. doi: 10.1093/cid/ciab025.
10
Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.米卡芬净的临床药代动力学和药效学。
Clin Pharmacokinet. 2018 Mar;57(3):267-286. doi: 10.1007/s40262-017-0578-5.
本文引用的文献
1
High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.大剂量米卡芬净用于患有侵袭性和中枢神经系统念珠菌病的早产新生儿和婴儿
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7333-7339. doi: 10.1128/AAC.01172-16. Print 2016 Dec.
2
Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation.体外膜肺氧合支持下米卡芬净在婴儿中的药代动力学及安全性
Pediatr Infect Dis J. 2016 Nov;35(11):1204-1210. doi: 10.1097/INF.0000000000001268.
3
Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study.米卡芬净在日本儿科患者中的安全性和有效性：一项上市后监测研究的结果。
J Pediatr Hematol Oncol. 2015 Jul;37(5):e285-91. doi: 10.1097/MPH.0000000000000343.
4
Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study.米卡芬净用于治疗儿童和成人确诊及疑似侵袭性念珠菌病：一项多中心前瞻性观察性研究的结果
BMC Infect Dis. 2014 Dec 31;14:725. doi: 10.1186/s12879-014-0725-7.
5
Neonatal candidiasis: diagnosis, prevention, and treatment.新生儿念珠菌病：诊断、预防及治疗
J Infect. 2014 Nov;69 Suppl 1(0 1):S19-22. doi: 10.1016/j.jinf.2014.07.012. Epub 2014 Aug 13.
6
The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system--tools for "meaningful use" in continuous quality improvement.Pediatrix BabySteps 数据仓库和 Pediatrix QualitySteps 改善项目系统——持续质量改进中“有意义使用”的工具。
Clin Perinatol. 2010 Mar;37(1):49-70. doi: 10.1016/j.clp.2010.01.016.
7
Population pharmacokinetics of micafungin in neonates and young infants.新生儿和婴儿中米卡芬净的群体药代动力学。
Antimicrob Agents Chemother. 2010 Jun;54(6):2633-7. doi: 10.1128/AAC.01679-09. Epub 2010 Mar 22.
8
Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.极低出生体重儿的新生儿念珠菌病：18至22个月时的危险因素、死亡率及神经发育结局
Pediatrics. 2006 Jan;117(1):84-92. doi: 10.1542/peds.2004-2292.
Zotero 插件